For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results